Looking At Novo Nordisk's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk (NYSE:NVO), and it’s something market players shouldn’t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga’s options scanner highlighted 45 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 35% leaning bullish and 37% bearish. Among these notable options, 12 are puts, totaling $1,065,123, and 33 are calls, amounting to $2,100,582.

Projected Price Targets

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $80.0 for Novo Nordisk over the last 3 months.

Volume & Open Interest Development

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk’s options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk’s substantial trades, within a strike price spectrum from $30.0 to $80.0 over the preceding 30 days.

Novo Nordisk Call and Put Volume: 30-Day Overview

Biggest Options Spotted:

SymbolPUT/CALLTrade TypeSentimentExp. DateAskBidPriceStrike PriceTotal Trade PriceOpen InterestVolume

NVO
PUT
SWEEP
BULLISH
06/18/26
$4.4
$4.3
$4.38
$55.00
$343.2K
15.1K
1.2K

NVO
CALL
TRADE
BULLISH
06/18/26
$13.0
$12.75
$13.0
$50.00
$162.5K
9.0K
122

NVO
PUT
SWEEP
BEARISH
09/18/26
$3.7
$3.6
$3.67
$50.00
$141.8K
8.2K
1.5K

NVO
CALL
SWEEP
BULLISH
01/16/26
$9.6
$9.4
$9.6
$50.00
$130.5K
16.9K
212

NVO
PUT
SWEEP
BULLISH
09/18/26
$3.75
$3.6
$3.63
$50.00
$124.4K
8.2K
1.9K

About Novo Nordisk

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Following our analysis of the options activities associated with Novo Nordisk, we pivot to a closer look at the company’s own performance.

Current Position of Novo Nordisk

• Currently trading with a volume of 12,874,734, the NVO’s price is up by 2.24%, now at $60.13.
• RSI readings suggest the stock is currently may be overbought.
• Anticipated earnings release is in 23 days.

Professional Analyst Ratings for Novo Nordisk

A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $73.5.

• An analyst from CICC has revised its rating downward to Outperform, adjusting the price target to $73.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements.